Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexadecane SCHEMBL2456024 | 1.00 | TSHR (0.53) | TSHRTHRBCNR2HTTCNR1 | |
| Decane SCHEMBL8857602 | 1.00 | TSHR (0.53) | TSHRTHRBCNR2HTTCNR1 | |
| Dodecane SCHEMBL2452907 | 1.00 | TSHR (0.53) | TSHRTHRBCNR2HTTCNR1 | |
| Hexane SCHEMBL28262924 | 0.97 | TSHR (0.47) | TSHRTHRBCNR2HTTCNR1 | |
| Hexane SCHEMBL28364568 | 0.93 | CNR2 (0.44) | TSHRTHRBCNR2HTTCNR1 | |
| SCHEMBL9321144 | 0.87 | TSHR (0.65) | TSHRTHRBCNR2HTTCNR1 | |
| SCHEMBL8732532 | 0.84 | PTGS2 (0.59) | HTTPTGS2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL28197360 | 0.84 | PTGS2 (0.59) | HTTPTGS2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL10413816 | 0.84 | PTGS2 (0.59) | HTTPTGS2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL28072148 | 0.84 | PTGS2 (0.59) | HTTPTGS2ALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2487178-A1 | PYRAZOLOTHIAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | CRHR1, CNR1, AGTR1 | TSHR 132/4885THRB 942/4885CNR2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.